US and European emergency authorisation of its Covid-19 vaccine supported full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns. On the opposite hand Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing the coronavirus.
If regulators approve any in coming weeks, the businesses have said distribution could begin soon .But few Asian countries expect to receive big amounts initially. Here are estimated distribution timelines, supply deals announced and clinical trials being held within the region.
It has agreed to shop for 135 million doses: 34 million from AstraZeneca, 40 million from Novavax Inc, 10 million from Pfizer and 51 million from CSL Ltd.It expects delivery of three .8 million doses of AstraZeneca’s vaccine in January and February next year.
The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov 23 the positive late-state trial results of the candidate will allow it to hunt emergency use approval by year-end, before securing the OK for a full rollout by February or March.
India also expects a government-backed vaccine to be launched as early as February, while it conducts a late-stage trial of Sputnik V.
It announced a deal on Nov 27 for two .6 million doses of the AstraZeneca vaccine and is discussing a possible 1 million more, covering about 1% of a population of 108 million.It is also seeking 20 million to 50 million doses from Sinovac and is in talks with others, including Pfizer.Vaccine makers can seek approval from Philippine regulators albeit no clinical test is completed there.
China has not announced supply deals with Western drugmakers, which instead have partnered with private companies.AstraZeneca’s vaccine could also be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products plans annual production capacity of a minimum of 100 million doses by end-2020.
For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group plans a phase II clinical trial trial.Tibet Rhodiola Pharmaceutical Holding is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials in China.
China has also approved three vaccine candidates developed by Sinovac and state-owned Sinopharm for emergency use, and Sinopharm hopes its two candidates wil get conditional approval for general use this year.
Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by directly purchase from manufacturers, and should buy a further 15 million doses.
The government has said it hopes to start vaccinations within the half-moon next year.
It agreed to shop for 12.8 million doses of Pfizer vaccine, becoming the primary country in Southeast Asia to announce a affect the U.S. drugmaker after some expressed reservations over the necessity for ultra-cold storage.
Pfizer will deliver the primary batch of 1 million doses within the half-moon of next year.
Japan has deals to shop for 120 million doses from Pfizer/BioNTech within the half of next year and 120 million from AstraZeneca, the primary 30 million of which can be shipped by March 2021, and 250 million from Novavax.
It is also in talks with Johnson & Johnson and features a affect Shionogi & Co.
Experts said vaccine makers would wish to conduct a minimum of phase I clinical trial and II trials in Japan before seeking approval.
It aims to secure vaccines for 10 million people from COVAX and for 20 million more from separate deals with drugmakers by year-end.
It has an “optional purchase” arrangement with COVAX to pick vaccines from specific makers. The timing of procurement and therefore the amount depend upon the output schedule of these vaccines, say health officials.Inoculation is probably going to start out within the second quarter of next year to permit time to watch possible side effects.
Grouped among 92 low- and middle-income economies, it's entitled to access vaccines through COVAX for a fifth of its population, or about 106 million to 107 million doses, if everyone gets two injections.Indonesia is testing Sinovac vaccine and preparing mass vaccination for medical staff and other frontline workers to start out as soon as late January.
A government official COVAX vaccines would cover only 20% of the population and therefore the country is probably going to possess an opportunity to secure separate deals soon, as demand is extremely high.
Bangladesh signed a affect India’s Serum Institute to shop for 30 million doses of the AstraZeneca vaccine.
It also expects to receive 68 million doses from GAVI at a subsidised rate, a senior health ministry official said.
Check Here : Top 10 Best Car Accessories
Check Here : Top 10 Earphones in The world